Rodriguez-Iglesias Miguel, Calvo-Henríquez Christian, Martin-Jimenez Daniel, García-Lliberós Ainhoa, Maza-Solano Juan, Moreno-Luna Ramon, Izquierdo-Domínguez Adriana, Martínez-Capoccioni Gabriel, Alobid Isam
Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS) study group, Dubai, United Arab Emirates.
Service of Otolaryngology, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.
Curr Allergy Asthma Rep. 2025 Feb 5;25(1):13. doi: 10.1007/s11882-025-01192-y.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.
Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.
伴鼻息肉的慢性鼻-鼻窦炎（CRSwNP）是一种使人衰弱的炎症性疾病，对生活质量有显著影响。尽管治疗取得了进展，但复发很常见，这促使人们探索新的疗法，如针对2型免疫反应的单克隆抗体，特别是度普利尤单抗。本研究旨在评估度普利尤单抗治疗重度CRSwNP的真实世界证据（RWE），并将鼻窦结局与随机临床试验中观察到的结果进行比较。
观察到显著改善，度普利尤单抗治疗后SNOT-22平均评分降低37.2分。鼻息肉大小（NPS）平均下降3.6分。分析强调了度普利尤单抗的实际有效性，强调其在减少NPS和改善鼻部症状方面优于传统疗法。研究结果主张将度普利尤单抗纳入重度CRSwNP的标准治疗方案，提供一种有力的替代方案，有可能降低与当前管理策略相关的高复发率。这项研究强调了RWE在评估新药物治疗有效性方面的实用性，表明度普利尤单抗为患有这种具有挑战性疾病的患者带来了实实在在的现实益处。
